Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT ) 7.100 -0.100 (-1.39%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 89,922 Open 7.260 Bid (Size) 7.000 (4) Ask (Size) 7.170 (3) Prev. Close 7.200 Today's Range 7.000 - 7.500 52wk Range 5.850 - 15.20 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT) August 15, 2024 Via AB Newswire Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market July 18, 2024 Via AB Newswire Performance YTD -14.35% -14.35% 1 Month +7.25% +7.25% 3 Month +7.90% +7.90% 6 Month -23.41% -23.41% 1 Year -50.52% -50.52% More News Read More Precision Medicine M&A is Transforming the Future of the Biotech Industry June 17, 2024 Via AB Newswire 7 Penny Biotech Stocks to Triple Your Investment May 28, 2024 Via InvestorPlace Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference May 16, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Recap: Nuvectis Pharma Q3 Earnings November 08, 2023 Via Benzinga NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 May 07, 2024 Via InvestorPlace Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines April 08, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire 5 Healthcare Stocks to Buy for 2024 April 02, 2024 Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting March 19, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Present at the 36th Annual Roth Conference March 15, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 14, 2024 Via Benzinga Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer March 14, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023 March 05, 2024 Via InvestorPlace Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences February 09, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Participation at Upcoming Investor Conferences February 09, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session January 18, 2024 Via Benzinga Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma December 18, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer October 24, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session October 17, 2023 Via Benzinga Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation September 25, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 September 21, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial September 12, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 September 06, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.